Literature DB >> 12860911

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.

Naveed Sattar1, Allan Gaw, Olga Scherbakova, Ian Ford, Denis St J O'Reilly, Steven M Haffner, Chris Isles, Peter W Macfarlane, Chris J Packard, Stuart M Cobbe, James Shepherd.   

Abstract

BACKGROUND: The National Cholesterol Education Program (NCEP) recently proposed a simple definition for metabolic syndrome. Information on the prospective association of this definition for coronary heart disease (CHD) and type 2 diabetes is currently limited. METHODS AND
RESULTS: We used a modified NCEP definition with body mass index in place of waist circumference. Baseline assessments in the West of Scotland Coronary Prevention Study were available for 6447 men to predict CHD risk and for 5974 men to predict incident diabetes over 4.9 years of follow-up. Mean LDL cholesterol was similar but C-reactive protein was higher (P<0.0001) in the 26% of men with the syndrome compared with those without. Metabolic syndrome increased the risk for a CHD event [univariate hazard ratio (HR)=1.76 (95% CI, 1.44 to 2.15)] and for diabetes [univariate HR=3.50 (95% CI 2.51 to 4.90)]. Metabolic syndrome continued to predict CHD events (HR=1.30, 95% CI, 1.00 to 1.67, P=0.045) in a multivariate model incorporating conventional risk factors. Men with 4 or 5 features of the syndrome had a 3.7-fold increase in risk for CHD and a 24.5-fold increase for diabetes compared with men with none (both P<0.0001). C-reactive protein enhanced prognostic information for both outcomes. With pravastatin, men with the syndrome had similar risk reduction for CHD as compared with those without (HR, 0.73 and 0.69; pravastatin versus placebo).
CONCLUSIONS: A modified NCEP metabolic syndrome definition predicts CHD events, and, more strikingly, new-onset diabetes, and thus helps identify individuals who may receive particular benefit from lifestyle measures to prevent these diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12860911     DOI: 10.1161/01.CIR.0000080897.52664.94

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  275 in total

1.  Association of metabolic syndrome with development of new-onset diabetes after transplantation.

Authors:  Nathaniel D Bayer; Philip T Cochetti; Mysore S Anil Kumar; Valerie Teal; Yonghong Huan; Cataldo Doria; Roy D Bloom; Sylvia E Rosas
Journal:  Transplantation       Date:  2010-10-27       Impact factor: 4.939

Review 2.  Migraine and metabolism.

Authors:  G Casucci; V Villani; D Cologno; F D'Onofrio
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

3.  The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes.

Authors:  Birgitta Grundmark; Hans Garmo; Massimo Loda; Christer Busch; Lars Holmberg; Björn Zethelius
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

4.  Prevalence of metabolic syndrome in the clinical practice of general medicine in Italy.

Authors:  Giuliano Tocci; Andrea Ferrucci; Graziella Bruno; Elmo Mannarino; Giulio Nati; Bruno Trimarco; Massimo Volpe
Journal:  Cardiovasc Diagn Ther       Date:  2015-08

Review 5.  Paleolithic nutrition for metabolic syndrome: systematic review and meta-analysis.

Authors:  Eric W Manheimer; Esther J van Zuuren; Zbys Fedorowicz; Hanno Pijl
Journal:  Am J Clin Nutr       Date:  2015-08-12       Impact factor: 7.045

6.  Visceral adiposity index, hypertriglyceridemic waist and risk of diabetes: the China Health and Nutrition Survey 2009.

Authors:  T Du; X Sun; R Huo; X Yu
Journal:  Int J Obes (Lond)       Date:  2013-09-19       Impact factor: 5.095

Review 7.  Metabolic syndrome: demographic features, etiology, and clinical management.

Authors:  Kathleen L Wyne
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

Review 8.  Comprehensive Cardiovascular Risk Reduction and Cardiac Rehabilitation in Diabetes and the Metabolic Syndrome.

Authors:  Robert E Heinl; Devinder S Dhindsa; Elliot N Mahlof; William M Schultz; Johnathan C Ricketts; Tina Varghese; Amirhossein Esmaeeli; Marc P Allard-Ratick; Anthony J Millard; Heval M Kelli; Pratik B Sandesara; Danny J Eapen; Laurence Sperling
Journal:  Can J Cardiol       Date:  2016-07-22       Impact factor: 5.223

9.  Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: a UK population-based cross-sectional study.

Authors:  T Tillin; N Forouhi; D G Johnston; P M McKeigue; N Chaturvedi; I F Godsland
Journal:  Diabetologia       Date:  2005-03-10       Impact factor: 10.122

Review 10.  The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  R Kahn; J Buse; E Ferrannini; M Stern
Journal:  Diabetologia       Date:  2005-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.